Kidney Cancer Clinical Trial

A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).

Summary

The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC.

The study includes participants who:

are 18 years old or above and have mRCC
took medicines that use the bodies immunity to fight against cancer as their first choice of treatment
took other medicines after taking the above first choice of treatment

This is a study that looks into the data collected through a particular database from selected academic clinical sites participating in this study. The data of interest include:

the length of time between the start of a patient's treatment and the end of treatment
the length of time between the start of treatment and death
physician assessment of a patient's response to treatment

We will compare the experiences of people receiving different combinations of treatments and see if there are any differences in the effectiveness of these medicines.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosed with mRCC
Age 18 years or over at the time of mRCC diagnosis
Received IO combination treatment in 1L such as receiving ipilimumab + nivolumab or an axitinib-based regimen (ie, axitinib + pembrolizumab or axitinib + avelumab) as 1L
Received subsequent treatments following 1L (e.g., 2L, 3L)
Actively treated at an IMDC clinical center (to avoid incomplete data)

Exclusion Criteria:

- There are no exclusion criteria for this study

Study is for people with:

Kidney Cancer

Estimated Enrollment:

494

Study ID:

NCT05858749

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Pfizer Headquarters
New York New York, 10017, United States

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Estimated Enrollment:

494

Study ID:

NCT05858749

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.